Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use

A bispecific antibody that binds to death receptor 5 (DR5) and Fibroblast Activation Protein (FAP), comprising at least one antigen binding site specific for DR5, comprising

• (a) a heavy chain complementarity determining region 1 (CDR1) selected from the group consisting of SEQ ID NO.:1, SEQ ID NO.:17 and SEQ ID NO.:75;
• (b) a heavy chain complementarity determining region 2 (CDR2) selected from the group of SEQ ID NO.:2, SEQ ID NO.:18, SEQ ID NO.:25 and SEQ ID NO.:83;
• (c) a heavy chain complementarity determining region 3 (CDR3) selected from the group of SEQ ID NO.:3, SEQ ID NO.:19, SEQ ID NO.:84, SEQ ID NO.:96, SEQ ID NO.:98;
• SEQ ID NO.:104 and SEQ ID NO.:108;
• (d) a light chain CDR1 selected from the group of SEQ ID NO.:4, SEQ ID NO.:20, SEQ ID NO.:27 and SEQ ID NO.:86;
• (e) a light chain CDR2 selected from the group of SEQ ID NO.:5, SEQ ID NO.:21 and SEQ ID NO.:28;
• and
• (f) a light chain CDR3 selected from the group of SEQ ID NO.:6, SEQ ID NO.:22, SEQ ID NO.:87, SEQ ID NO.:99, SEQ ID NO.:105, SEQ ID NO.:109 and SEQ ID NO.:97;
• and at least one antigen binding site specific for FAP, comprising
• (a) a heavy chain CDR1 selected from the group of SEQ ID NO.:9 and SEQ ID NO.:33;
• (b) a heavy chain CDR2 selected from the group of SEQ ID NO.:10 and SEQ ID NO.:34;
• (c) a heavy chain CDR3 selected from the group of SEQ ID NO.:11 and SEQ ID NO.:35;
• (d) a light chain CDR1 selected from the group of SEQ ID NO.:12 and SEQ ID NO.:36;
• (e) a light chain CDR2 selected from the group of SEQ ID NO.:13 and SEQ ID NO.:37;
• (f) a light chain CDR3 selected from the group of SEQ ID NO.:14 and SEQ ID NO.:38.